Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
about
ROR1, an embryonic protein with an emerging role in cancer biologyThe dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesisNanoscale monitoring of drug actions on cell membrane using atomic force microscopyThe role of Ryk and Ror receptor tyrosine kinases in Wnt signal transductionThe pathogenesis of chronic lymphocytic leukemiaTherapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignanciesSilencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung AdenocarcinomaWnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.ROR1 expression correlated with poor clinical outcome in human ovarian cancerProtein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and MigrationThe B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cellsTumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cellsA novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.Targeting malignant B cells with an immunotoxin against ROR1ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy.Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin AmiR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic LeukemiaWnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.Antibody-based therapeutics for the treatment of human B cell malignanciesReceptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.Expression of ROR1 in patients with renal cancer--a potential diagnostic marker.High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.Critical signal transduction pathways in CLL.
P2860
Q26828533-E5F92579-8FEE-4F40-9FEA-38EA8E52BEEAQ26829919-32E41F41-B298-4CE2-BA03-C91CC3005296Q26852240-C0D9CB39-4404-4B08-B428-BEB21821014FQ26852972-2F42326F-2376-4DEE-B077-820A196F7D30Q27025715-B4DED03D-1DB7-4453-A594-F109466F5D48Q28478591-51F4C6B1-1087-422E-81D8-488BBC0CB57CQ28547292-131EAAE4-7955-49F5-8663-2B640985F5EEQ30008736-A8D1EA76-2769-4ADB-A82C-18044004AFFEQ33649606-A3AEC49C-F375-4DCB-AC9E-5D5279758C7AQ33779292-4219893A-E78F-4EF2-80D7-8C6B9FDCF422Q33884816-28C116E9-71B6-4CE0-8947-6A60AAC7A47FQ33942010-C4AFB8EE-7DDC-4F55-95EA-868F41C0D4D6Q34081881-F0C851C8-D376-4E9F-BE2D-B785D5CE89A8Q34158454-7F4CEC3F-8D3B-422B-8702-59EA18967722Q34189274-4ED7C3B7-458F-47A9-8196-D69987A5C2E6Q34219505-9D8F5A35-FC40-43ED-BE1D-80B1427C5826Q34374056-BCBF1BCA-7968-487F-96AE-AD89E942F351Q34534333-C5B3BE9F-2030-4F69-9CCD-0B980E13E538Q34674715-0B0FF846-7236-4CA2-9A8F-1F763177B52DQ34747359-2D5C56F5-0E4F-417B-8D24-8611C9795422Q34797406-B091C3F1-10F5-4DF0-86C4-7CCEA2C45587Q35029969-2EB0DC30-E961-4E35-B8A0-5BFED8F5A002Q35036351-7593D410-052A-4F30-9BDA-1ADF1B5277E2Q35200573-DB9358AE-3865-46B3-962E-E2C6552631C7Q35648352-0F41DCEE-1821-42D7-92E1-13EE6B7959EEQ35839793-3E4D9A16-73A2-4F60-B825-47E3D099D024Q35969887-85FAD0C6-C450-4A66-A729-EA808AEDD986Q35971763-68F5D107-0C67-4328-A485-46AE6A5D9950Q36194681-88F63FC0-39DA-4068-A6A4-60C7C20C9258Q36294199-B5CB6625-A99B-41B5-B1A2-D109599EC0F5Q36433018-5EAFD390-AD85-47DA-9D81-DF1E33783C76Q36471596-4DC8EE60-2B05-4BC1-9089-053829CAE9F7Q36515159-4B0DC5CE-3AD3-4FEA-A5D1-A50D93C6796BQ36907540-EC04BCDB-FF54-43B9-859C-72B96194DAD5Q37244349-53BE3A62-EA62-44A0-BA3A-BFEE522541FFQ37320359-AD2C3E31-98BB-43A7-84EA-5C434D316405Q37495234-675F424B-DC60-4461-AEBE-934F3414ECD4Q37522298-34645D37-5946-45DE-9814-FB6E941EEF42Q37528063-5F295223-C1B1-456B-AC27-8DB16DB8CD21Q37571068-71CA754E-94F0-46C9-B438-A5E374F72133
P2860
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Ror1, a cell surface receptor ...... a putative target for therapy.
@ast
Ror1, a cell surface receptor ...... a putative target for therapy.
@en
Ror1, a cell surface receptor ...... a putative target for therapy.
@nl
type
label
Ror1, a cell surface receptor ...... a putative target for therapy.
@ast
Ror1, a cell surface receptor ...... a putative target for therapy.
@en
Ror1, a cell surface receptor ...... a putative target for therapy.
@nl
prefLabel
Ror1, a cell surface receptor ...... a putative target for therapy.
@ast
Ror1, a cell surface receptor ...... a putative target for therapy.
@en
Ror1, a cell surface receptor ...... a putative target for therapy.
@nl
P2093
P356
P1476
Ror1, a cell surface receptor ...... a putative target for therapy.
@en
P2093
Ali Ahmad Bayat
Amir H Daneshmanesh
Anders Osterborg
Catharina Larsson
Eva Mikaelsson
Fazel Shokri
Hodjattallah Rabbani
Håkan Mellstedt
Mahmood Jeddi-Tehrani
Mahyar Ostadkarampour
P304
P356
10.1002/IJC.23587
P577
2008-09-01T00:00:00Z